VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$28.92+1.04 (+3.73%)
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.31 (−7.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.08B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.10
- Dividend yield
- –
- Free cash flow yield
- -16.31%
Fundamentals
- Net income
- -$401.90M
- EPS, diluted
- -$5.86
- Free cash flow
- -$338.91M
- Book value per share
- $5.68
- Diluted shares
- 72M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$415.76M
Net income
-$401.90M
EPS, diluted
-$5.86
Free cash flow
-$338.91M
Reported periodTrailing twelve months